SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nuvectis Reports Positive NXP200 Phase 1b Data in Gliomas

Nuvectis said the study demonstrated durable responses, including complete responses, in patients with BRAF V600-mutated recurrent or progressive gliomas.

NVCT

Related stories